• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      New patent laws lure pharma MNCs to India

      Posted AtThe Economic Times

      India is increasingly becoming the darling of pharma MNCs, who are vying with each other to set up operations here. One of the main triggers for this growth is the change in the country's patent laws.

      Haruo Naito, president and CEO of Eisai, recently made his first trip to India. If anything, it's a clear sign that Japan's fourth largest pharmaceutical company has big plans for India. The company has just set up its operations in India and has already rolled out two products into the domestic market.

      "One factor that played a role in bringing Eisai to India is the passing of product patent law," says Deepak Naik, MD of Eisai Pharmaceuticals India. The other factor was that Eisai's early experience in the country gave a positive sign on the potential of the country.

      "We outlicensed our product, Methycobal, to Wockhardt a few years ago and that product created a market of Rs 150 crore," Mr Naik said. Two months ago, Eisai launched two more products -- Aricept and Parit (being marketed by GlaxoSmithKline) -- and both are doing "very well."

      What's more, Eisai is now looking at other options for taking advantage of India's growth. "We are doing the feasibility for other aspects of business," said Mr Naik. Some of the future investments could be in R&D and clinical trials.

      November 18, 2005


      Share this Article!

    Back to top^